10/26/2025

Janusmed kön och genus

Janusmed kön och genus – Stivarga

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Regorafenib

Regorafenib

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Yang Y, Wang G, He J, Ren S, Wu F, Zhang J et al. Gender differences in colorectal cancer survival: A meta-analysis. Int J Cancer. 2017;141(10):1942-1949.

  2. Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC et al. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc. 2022;85(5):554-565.

  3. Pang C, Li JM, Wang Z, Luo YC, Cheng ZG, Han ZY et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024;22(2):305-314.

  4. Ren X, Wang G, Chen J, Liu L. A population-based analysis of gender differences in survival outcomes for gastric gastrointestinal stromal tumors. J Gastrointest Surg. 2025;29(6):102055.

  5. Delahousse J, Wagner AD, Borchmann S, Adjei AA, Haanen J, Burgers F et al. Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. ESMO Open. 2024;9(12):104002.

  6. Keunecke A, Hoefman S, Drenth HJ, Zisowsky J, Cleton A, Ploeger BA. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. Br J Clin Pharmacol. 2020;86(12):2362-2376.

  7. Barzi A. Review of third-line treatment strategies in refractory metastatic colorectal cancer. Clin Adv Hematol Oncol. 2024;22 Suppl 4(5):3-10.

  8. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12.

  9. Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P et al. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021;20(4):326-333.

  10. Stivarga (regorafenib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-02-07, cited 2025-10-03]

  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Yang Y, Wang G, He J, Ren S, Wu F, Zhang J et al. Gender differences in colorectal cancer survival: A meta-analysis. Int J Cancer. 2017;141(10):1942-1949.
  2. Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC et al. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc. 2022;85(5):554-565.
  3. Pang C, Li JM, Wang Z, Luo YC, Cheng ZG, Han ZY et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024;22(2):305-314.
  4. Ren X, Wang G, Chen J, Liu L. A population-based analysis of gender differences in survival outcomes for gastric gastrointestinal stromal tumors. J Gastrointest Surg. 2025;29(6):102055.
  5. Delahousse J, Wagner AD, Borchmann S, Adjei AA, Haanen J, Burgers F et al. Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. ESMO Open. 2024;9(12):104002.
  6. Keunecke A, Hoefman S, Drenth HJ, Zisowsky J, Cleton A, Ploeger BA. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. Br J Clin Pharmacol. 2020;86(12):2362-2376.
  7. Barzi A. Review of third-line treatment strategies in refractory metastatic colorectal cancer. Clin Adv Hematol Oncol. 2024;22 Suppl 4(5):3-10.
  8. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12.
  9. Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P et al. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021;20(4):326-333.
  10. Stivarga (regorafenib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-02-07, cited 2025-10-03]
  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]